PI3 Stock Overview
Operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Gubra A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 68.60 |
| 52 Week High | DKK 101.00 |
| 52 Week Low | DKK 12.46 |
| Beta | 0 |
| 11 Month Change | -9.26% |
| 3 Month Change | -10.68% |
| 1 Year Change | 387.22% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 373.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| PI3 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 6.9% | 4.2% | 4.5% |
| 1Y | 387.2% | 3.8% | 13.5% |
Return vs Industry: PI3 exceeded the German Life Sciences industry which returned 3.8% over the past year.
Return vs Market: PI3 exceeded the German Market which returned 13.5% over the past year.
Price Volatility
| PI3 volatility | |
|---|---|
| PI3 Average Weekly Movement | 15.1% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PI3's share price has been volatile over the past 3 months.
Volatility Over Time: PI3's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 235 | Henrik Blou | www.gubra.dk |
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally. The company operates through CRO, Discovery & Partnerships, and Gubra Green segments. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, assays and molecular pharmacology, bioinformatics, bioanalysis, next gen sequencing, and 2D and 3D imaging.
Gubra A/S Fundamentals Summary
| PI3 fundamental statistics | |
|---|---|
| Market cap | €1.12b |
| Earnings (TTM) | -€6.24m |
| Revenue (TTM) | €30.02m |
37.3x
P/S Ratio-179.5x
P/E RatioIs PI3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PI3 income statement (TTM) | |
|---|---|
| Revenue | DKK 223.82m |
| Cost of Revenue | DKK 92.35m |
| Gross Profit | DKK 131.47m |
| Other Expenses | DKK 177.99m |
| Earnings | -DKK 46.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 28, 2025
| Earnings per share (EPS) | -2.85 |
| Gross Margin | 58.74% |
| Net Profit Margin | -20.79% |
| Debt/Equity Ratio | 0% |
How did PI3 perform over the long term?
See historical performance and comparison